Saturday, 3 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 18, 2026

Polestar starts largest model offensive in its history: four new cars in three years

View original at finance.yahoo.com
Polestar starts largest model offensive in its history: four new cars in three years Polestar 18 FebruaryPolestar 2 successorPolestar 4 variantPolestar 7 Polestar 5 to start deliveries in summer, followed by a new variant of Polestar 4 in Q4 of 2026 Completely new successor of the iconic Polestar 2 in 2027 and compact…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Polestar 5 brings new level of performance and luxury to grand-tourer segment with incredible handling and lightweight bonded aluminium platform

    80% confidence

  • New Polestar 4 variant will set new standards combining space of estate and versatility of SUV with dynamic performance

    80% confidence

  • Company expects low double-digit retail volume growth in 2026 with disciplined approach

    80% confidence

  • Targeting the heart of the EV market where customer demand and profit pools are high

    80% confidence

  • Polestar launching largest model offensive in history with four premium EVs coming to market within three years

    80% confidence

  • Polestar set to become one of winners of automotive industry's transformation

    80% confidence

  • Polestar 7 entering largest EV segment in Europe (compact SUV) which accounts for approximately one-third of total BEV volumes in 2025

    80% confidence

  • Company aims to focus more on retail channel supported by continued network expansion and attractive model line-up

    80% confidence

  • 2025 was best year ever in terms of retail sales

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com